Advance Market Commitment

Advance Market Commitment
Name	Advance Market Commitment
Type	Incentive mechanism
Area served	Global

Advance Market Commitment

Advance Market Commitment is a public policy mechanism that commits purchasers to buy specified quantities of a future product at a predetermined price to incentivize research and development by suppliers. It has been used in international health and development contexts to accelerate creation and distribution of vaccines and diagnostics by linking promised demand with funding pledges and procurement guarantees. Proponents cite its role in mobilizing partnerships among donors, Gavi, the Vaccine Alliance, Bill & Melinda Gates Foundation, World Bank, Health impact fund, and pharmaceutical manufacturers; critics point to debates raised by World Health Organization, Médecins Sans Frontières, and academic economists.

Definition and purpose

An Advance Market Commitment is designed to alter risk–reward calculations faced by firms such as GlaxoSmithKline, Pfizer, Sanofi, AstraZeneca, and Johnson & Johnson by guaranteeing a market for products meeting defined specifications, thereby encouraging investment in technologies of interest to actors including UNICEF, Pan American Health Organization, Global Fund to Fight AIDS, Tuberculosis and Malaria, and national procurement agencies like United States Agency for International Development and UK Department for International Development. The mechanism aims to overcome barriers identified in reports from World Bank Group, International Monetary Fund, Organisation for Economic Co-operation and Development, and scholars at Harvard University, Massachusetts Institute of Technology, and London School of Economics by aligning incentives across donors, manufacturers, and implementing partners such as PATH and The Rockefeller Foundation.

History and development

Proposals for demand-side guarantees trace to economic literature from authors linked to University of Chicago, Yale University, and Stanford University and to policy advocacy by actors including Bill Gates, George W. Bush administration advisers, and civil society groups such as Oxfam and Doctors Without Borders (Médecins Sans Frontières). The first large-scale implementation targeting pneumococcal conjugate vaccines involved commitments coordinated by Gavi, the Vaccine Alliance, backed by donors including Canada, Italy, Norway, Russia, United Kingdom, and private funders like Clinton Foundation allies, guided by technical work at Center for Global Development and economists from University of Chicago and University of California, Berkeley. Subsequent iterations and pilots engaged organizations such as Coalition for Epidemic Preparedness Innovations and initiatives discussed at meetings of World Health Assembly and Global Vaccine Summit.

Design and mechanisms

AMCs commonly specify product attributes, target populations, procurement volumes, and price ceilings, and they use legal instruments and escrowed funds managed by institutions like World Bank or procurement partners such as UNICEF Supply Division and Gavi, the Vaccine Alliance. Contractual frameworks draw on procurement law precedents from European Commission, United Nations, and national agencies including Centers for Disease Control and Prevention procurement rules; technical evaluation often relies on regulators like European Medicines Agency and U.S. Food and Drug Administration and guidance from World Health Organization prequalification. Economic design elements incorporate advance purchase agreements, milestone payments, push mechanisms modeled on historic programs like the Manhattan Project-era procurement and prize structures akin to the XPRIZE and Ansari X Prize, and are informed by analyses from National Bureau of Economic Research and policy centers at Brookings Institution and Carnegie Endowment for International Peace.

Applications and case studies

Notable case studies include the pneumococcal vaccine AMC coordinated by Gavi, the Vaccine Alliance and administered with support from World Bank financing and pledges from the Bill & Melinda Gates Foundation and donor governments, which interacted with manufacturers including Wyeth (now part of Pfizer), GlaxoSmithKline, and Merck & Co., Inc. to expand supply for low- and middle-income countries. Other applications considered or piloted involve candidates for RSV vaccines, malaria vaccines developed with researchers at PATH Malaria Vaccine Initiative and Oxford University, and diagnostics for Ebola during outbreaks coordinated with Médecins Sans Frontières response teams and Centers for Disease Control and Prevention laboratories. Cross-sector pilots include energy and climate technologies discussed at United Nations Framework Convention on Climate Change conferences and prize-like procurements led by NASA and European Space Agency.

Economic effects and critiques

Analyses in journals and policy briefs from scholars at Harvard Kennedy School, Princeton University, Columbia University, and think tanks like Center for Global Development and International Vaccine Institute suggest AMCs can reduce market uncertainty, accelerate time-to-market, and leverage donor funds to induce private R&D investment; empirical assessments of the pneumococcal AMC examine outcomes published by Lancet, New England Journal of Medicine, and reports circulated to Gavi, the Vaccine Alliance donors. Critics from Médecins Sans Frontières, Oxfam, and academics at University of Oxford question opportunity costs, price-setting transparency, and potential rent capture by large firms such as GlaxoSmithKline and Pfizer; legal scholars from Yale Law School and Columbia Law School note procurement governance and competition law interactions, while economists at London School of Economics analyze alternative mechanisms like prizes, patent pools exemplified by Medicines Patent Pool, and tiered pricing.

Governance, implementation, and stakeholders

Successful implementation requires coordination among donors such as Bill & Melinda Gates Foundation, sovereign states like United Kingdom, Canada, Norway, multilateral banks including World Bank, procurement agencies such as UNICEF, technical partners like World Health Organization and Gavi, the Vaccine Alliance, academic evaluators from London School of Hygiene & Tropical Medicine and Johns Hopkins Bloomberg School of Public Health, civil society organizations including Médecins Sans Frontières and Oxfam, and private manufacturers including Sanofi and AstraZeneca. Oversight arrangements often involve independent evaluation panels drawing experts from National Academies of Sciences, Engineering, and Medicine, audit institutions like International Organization of Supreme Audit Institutions, and implementation partners such as PATH and Clinton Health Access Initiative to monitor procurement compliance, equity outcomes, and post-deployment surveillance coordinated with WHO Global Outbreak Alert and Response Network.

Category:Health financing